1. Exact subject (e.g., TB under NTEP, diagnostics, treatment regimens, programmatic management)
2. Exam type (MD university exam, NEET SS, INI-SS, viva)
3. Format you want
   • bullet notes
   • long answer format
   • short notes
   • flowcharts/tables
4. Depth (quick revision vs exhaustive)

NTEP (National TB Elimination Programme) for MD Exams - High Yield Notes

1) Introduction

• NTEP is India’s TB control programme (earlier RNTCP).
• Renamed to align with target of TB elimination.
• Goal: eliminate TB in India by 2025 (programmatic target).

2) Objectives (exam points)

• Early diagnosis of all TB cases.
• Universal drug susceptibility testing (UDST).
• Prompt, complete treatment with patient support.
• Reduce TB deaths, catastrophic costs, and transmission.
• TB preventive treatment in eligible contacts/high-risk groups.
• Integrate public + private sector notification and treatment.

3) Case Finding

• Passive case finding: symptomatic persons presenting to health facilities.
• Active case finding (ACF): targeted screening in high-risk populations.
• Vulnerable groups: contacts, PLHIV, diabetes, malnourished, urban slums, tribal areas, prisoners, miners, migrants, elderly, etc.

4) Presumptive TB (important definition)

• Any person with symptoms/signs suggestive of TB:
  • Cough ≥2 weeks, fever, weight loss, night sweats, hemoptysis
  • For EPTB: site-specific symptoms (lymph node swelling, pleural effusion, meningitis features, etc.)

5) Diagnostic Algorithm (very important)

• Initial microbiological test (preferred): NAAT
  • CBNAAT/Truenat for MTB detection + rifampicin resistance.
• Smear microscopy still used in some settings for follow-up/triage.
• Chest X-ray supportive, not confirmatory alone.
• If microbiology negative but strong clinical-radiological suspicion: clinical diagnosis possible, especially EPTB/pediatric.
• UDST principle: perform DST early for all diagnosed TB patients.

6) Classification of TB

1. By site
   • Pulmonary TB (PTB)
   • Extrapulmonary TB (EPTB)
2. By microbiological status
   • Microbiologically confirmed
   • Clinically diagnosed
3. By drug resistance
   • Drug-sensitive TB (DS-TB)
   • RR-TB/MDR-TB/pre-XDR/XDR (as per resistance pattern)
4. By treatment history
   • New
   • Previously treated

7) Drug-Sensitive TB Treatment (MD must-know)

• Daily fixed-dose combinations (weight-band based).
• Intensive Phase (IP): 2 months HRZE
• Continuation Phase (CP): 4 months HRE (program schedules may update; always mention latest guideline adaptation)
• Pyridoxine supplementation where indicated.
• Monitor adherence, adverse events, weight-based dose adjustments.

8) Drug-Resistant TB (overview)

• RR/MDR-TB: resistance to rifampicin ± isoniazid.
• Current NTEP emphasizes all-oral longer/shorter regimens based on eligibility and DST pattern.
• Key drugs: bedaquiline, linezolid, levo/moxifloxacin, clofazimine, cycloserine, etc. (regimen individualized/programmatic per guideline).
• Injectable-containing regimens are largely phased out in many protocols.
• Close monitoring for toxicity (QT prolongation, myelosuppression, neuropathy, etc.).

9) Treatment Adherence & Patient Support

• Nikshay: case-based digital TB platform for notification, tracking, outcomes, DBT.
• DBT/Nikshay Poshan Yojana: nutritional support benefit for TB patients.
• Adherence support through treatment supporters, digital tools, counseling, family engagement.
• Different from older “DOTS-only” paradigm; now patient-centric adherence model.

10) Private Sector Engagement (frequent viva topic)

• Mandatory TB notification.
• Private provider involvement via PPSA-like mechanisms in many areas.
• Free diagnostics/drugs linkages via NTEP.
• Notification and treatment outcome capture in Nikshay.

11) TB-HIV Collaborative Activities

• Bidirectional screening:
  • All TB patients tested for HIV.
  • PLHIV screened regularly for TB.
• Cotrimoxazole preventive therapy and early ART in TB-HIV coinfection.
• TB preventive treatment in eligible PLHIV after ruling out active TB.

12) TB Preventive Treatment (TPT)

• For high-risk groups after excluding active TB:
  • Household contacts (especially children)
  • PLHIV and other eligible groups per guideline
• Regimens may include isoniazid-based or rifapentine-based options depending on national policy updates.

13) Pediatric TB (must mention)

• Often paucibacillary; microbiological confirmation may be difficult.
• Gastric aspirate/induced sputum/NAAT where feasible.
• Contact tracing is crucial.
• TPT strongly emphasized in child contacts.

14) Program Structure (administrative)

• Central TB Division (national level)
• State TB Cells
• District TB Centres
• TB Units, Designated Microscopy Centres/NAAT sites, DR-TB centres
• Lab network with quality assurance and specimen transport systems.

15) Recording & Reporting (exam short note)

• Standardized treatment outcome definitions:
  • Cured
  • Treatment completed
  • Failure
  • Died
  • Lost to follow-up
  • Not evaluated
• Cohort analysis for program performance.
• Real-time data capture through Nikshay.

16) Key NTEP Strategies (theory question)

• Detect - Treat - Prevent - Build (often used framework variants in policy communication)
• Decentralized, patient-centric care.
• Digital surveillance and direct benefit transfer.
• Multisectoral accountability framework.
• Community engagement and stigma reduction.

17) Differences: DOTS vs NTEP (very high yield)

• DOTS era: emphasis on directly observed therapy + sputum microscopy-based approach.
• NTEP era:
  • Elimination goal
  • Universal molecular diagnostics
  • UDST
  • DR-TB all-oral regimens
  • Digital tracking (Nikshay)
  • Nutritional/social support
  • Stronger private sector integration
  • Preventive therapy expansion.

18) Common MD Viva Questions

1. Why was RNTCP renamed NTEP?
2. What is UDST and why important?
3. Diagnostic role of CBNAAT/Truenat?
4. Define RR-TB, MDR-TB, pre-XDR, XDR.
5. How do you manage household contacts?
6. What is Nikshay Poshan Yojana?
7. Enumerate treatment outcomes under NTEP.
8. How is TB-HIV collaboration implemented?
9. Outline DR-TB adverse effect monitoring.
10. Compare DOTS and NTEP.

• “10-mark long answer” ready format
• “5-mark short note” version
• one-page last-minute revision table for NTEP.